Novel genetic test for breast cancer

Article

The SPOT-Light HER2 CISH kit a genetic test that measures the number of copies of the HER2 gene in breast tumor tissue received approval recently from the Food and Drug Administration.

The SPOT-Light HER2 CISH kit‑a genetic test that measures the number of copies of the HER2 gene in breast tumor tissue‑received approval recently from the Food and Drug Administration for the identification of patients who might benefit from treatment with the drug trastuzumab (Herceptin).

The FDA’s approval is based on studies in the United States and Finland, which supported the accuracy of SPOT-Light, manufactured by Invitrogen Corp. of Carlsbad, CA.

During the test, a small sample of tumor tissue is stained with a chemical that causes color changes in HER2 genes. Unlike existing tests, which require fluorescent microscopes, SPOT-Light reveals changes that can be observed with a standard microscope. In addition, the test allows labs to store the tissue for future reference.

“When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer,” Daniel Schultz, MD, director of the FDA’s Center for Devices and Radiological Health, said in a statement.

FDA News Release: FDA Approves New Genetic Test for Patients with Breast Cancer. Available at:

http://www.fda.gov/bbs/topics/NEWS/2008/NEW01857.html

. Accessed August 7, 2008.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.